239 related articles for article (PubMed ID: 36686762)
1. Antibody-drug conjugates and predictive biomarkers in advanced urothelial carcinoma.
Fenton SE; VanderWeele DJ
Front Oncol; 2022; 12():1069356. PubMed ID: 36686762
[TBL] [Abstract][Full Text] [Related]
2. Antibody-drug conjugates targeting HER2 for the treatment of urothelial carcinoma: potential therapies for HER2-positive urothelial carcinoma.
Shih CH; Lin YH; Luo HL; Sung WW
Front Pharmacol; 2024; 15():1326296. PubMed ID: 38572425
[TBL] [Abstract][Full Text] [Related]
3. A novel strategy for treatment of bladder cancer: Antibody-drug conjugates.
Kim JH; Chang IH
Investig Clin Urol; 2022 Jul; 63(4):373-384. PubMed ID: 35670004
[TBL] [Abstract][Full Text] [Related]
4. Antibody-Drug Conjugates in Bladder Cancer.
Vlachostergios PJ; Jakubowski CD; Niaz MJ; Lee A; Thomas C; Hackett AL; Patel P; Rashid N; Tagawa ST
Bladder Cancer; 2018 Jul; 4(3):247-259. PubMed ID: 30112436
[TBL] [Abstract][Full Text] [Related]
5. Antibody-Drug Conjugates in Urothelial Carcinoma: A New Therapeutic Opportunity Moves from Bench to Bedside.
Ungaro A; Tucci M; Audisio A; Di Prima L; Pisano C; Turco F; Delcuratolo MD; Di Maio M; Scagliotti GV; Buttigliero C
Cells; 2022 Feb; 11(5):. PubMed ID: 35269424
[TBL] [Abstract][Full Text] [Related]
6. Antibody-drug conjugates in urinary tumors: clinical application, challenge, and perspectives.
Li K; Xie G; Deng X; Zhang Y; Jia Z; Huang Z
Front Oncol; 2023; 13():1259784. PubMed ID: 38173833
[TBL] [Abstract][Full Text] [Related]
7. Antibody-drug conjugates for the treatment of urothelial carcinoma.
Ravi P; McGregor BA
Expert Opin Biol Ther; 2021 Jul; 21(7):915-922. PubMed ID: 32589063
[TBL] [Abstract][Full Text] [Related]
8. Antibody-drug conjugates: the evolving field of targeted chemotherapy for breast cancer treatment.
Nader-Marta G; Molinelli C; Debien V; Martins-Branco D; Aftimos P; de Azambuja E; Awada A
Ther Adv Med Oncol; 2023; 15():17588359231183679. PubMed ID: 37435563
[TBL] [Abstract][Full Text] [Related]
9. Targeting nectin-4 by antibody-drug conjugates for the treatment of urothelial carcinoma.
Wong JL; Rosenberg JE
Expert Opin Biol Ther; 2021 Jul; 21(7):863-873. PubMed ID: 34030536
[TBL] [Abstract][Full Text] [Related]
10. Trop-2 protein as a therapeutic target: A focused review on Trop-2-based antibody-drug conjugates and their predictive biomarkers.
Vranic S; Gatalica Z
Bosn J Basic Med Sci; 2022 Feb; 22(1):14-21. PubMed ID: 34181512
[TBL] [Abstract][Full Text] [Related]
11. Antibody-Drug Conjugates in the Treatment of Urothelial Cancer.
Singh AM; Guevara-Patino JA; Wang X; Li R; Sonpavde G; Jain RK
BioDrugs; 2023 Jul; 37(4):505-520. PubMed ID: 37256534
[TBL] [Abstract][Full Text] [Related]
12. Recent Advances in the Development of Antibody-Drug Conjugates in Urothelial Cancer.
Alhalabi O; Altameemi L; Campbell MT; Meric-Bernstam F
Cancer J; 2022 Nov-Dec 01; 28(6):417-422. PubMed ID: 36383903
[TBL] [Abstract][Full Text] [Related]
13. 'Targeting' Improved Outcomes with Antibody-Drug Conjugates in Non-Small Cell Lung Cancer-An Updated Review.
Verma S; Breadner D; Raphael J
Curr Oncol; 2023 Apr; 30(4):4329-4350. PubMed ID: 37185443
[TBL] [Abstract][Full Text] [Related]
14. The Evolving Landscape of Antibody-Drug Conjugates for Urothelial Carcinoma.
Abel M; Burkenroad A; Sun A; Lu E; Stefanoudakis D; Drakaki A
Clin Genitourin Cancer; 2021 Jun; 19(3):183-193. PubMed ID: 33558159
[TBL] [Abstract][Full Text] [Related]
15. Antibody-Drug Conjugates in Urothelial Carcinomas.
Sarfaty M; Rosenberg JE
Curr Oncol Rep; 2020 Feb; 22(2):13. PubMed ID: 32008109
[TBL] [Abstract][Full Text] [Related]
16. Antibody-Drug Conjugates for the Treatment of Renal Cancer: A Scoping Review on Current Evidence and Clinical Perspectives.
Sganga S; Riondino S; Iannantuono GM; Rosenfeld R; Roselli M; Torino F
J Pers Med; 2023 Aug; 13(9):. PubMed ID: 37763107
[TBL] [Abstract][Full Text] [Related]
17. Antibody drug conjugates in gastrointestinal cancer: From lab to clinical development.
Singh D; Dheer D; Samykutty A; Shankar R
J Control Release; 2021 Dec; 340():1-34. PubMed ID: 34673122
[TBL] [Abstract][Full Text] [Related]
18. Enfortumab Vedotin-ejfv: A First-in-Class Anti-Nectin-4 Antibody-Drug Conjugate for the Management of Urothelial Carcinoma.
Halford Z; Anderson MK; Clark MD
Ann Pharmacother; 2021 Jun; 55(6):772-782. PubMed ID: 32945172
[TBL] [Abstract][Full Text] [Related]
19. Implementing antibody-drug conjugates (ADCs) in HER2-positive breast cancer: state of the art and future directions.
Ferraro E; Drago JZ; Modi S
Breast Cancer Res; 2021 Aug; 23(1):84. PubMed ID: 34380530
[TBL] [Abstract][Full Text] [Related]
20. Perspectives on the future of urothelial carcinoma therapy: chemotherapy and beyond.
Bianchi A; von Deimling M; Pallauf M; Yanagisawa T; Kawada T; Mostafaei H; Quhal F; Laukhtina E; Rajwa P; Majdoub M; Motlagh RS; Pradere B; Karakiewicz PI; Cerruto MA; Antonelli A; Shariat SF
Expert Opin Pharmacother; 2023 Feb; 24(2):177-195. PubMed ID: 36440477
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]